157 related articles for article (PubMed ID: 36764998)
1. The modulation of iron metabolism affects the Rhabdomyosarcoma tumor growth in vitro and in vivo.
Asperti M; Cantamessa L; Gryzik M; Bugatti M; Codenotti S; Denardo A; Vermi W; Fanzani A; Poli M
Clin Exp Med; 2023 Oct; 23(6):2487-2502. PubMed ID: 36764998
[TBL] [Abstract][Full Text] [Related]
2. Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype.
Rossetti A; Petragnano F; Milazzo L; Vulcano F; Macioce G; Codenotti S; Cassandri M; Pomella S; Cicchetti F; Fasciani I; Antinozzi C; Di Luigi L; Festuccia C; De Felice F; Vergine M; Fanzani A; Rota R; Maggio R; Polimeni A; Tombolini V; Gravina GL; Marampon F
Int J Radiat Biol; 2021; 97(7):943-957. PubMed ID: 33979259
[TBL] [Abstract][Full Text] [Related]
3. Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines.
Codenotti S; Poli M; Asperti M; Zizioli D; Marampon F; Fanzani A
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1717-1730. PubMed ID: 29971532
[TBL] [Abstract][Full Text] [Related]
4. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
[TBL] [Abstract][Full Text] [Related]
5. The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo.
Xu N; Hua Z; Ba G; Zhang S; Liu Z; Thiele CJ; Li Z
J Exp Clin Cancer Res; 2019 Mar; 38(1):118. PubMed ID: 30850026
[TBL] [Abstract][Full Text] [Related]
6. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
[TBL] [Abstract][Full Text] [Related]
8. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.
Niesen J; Brehm H; Stein C; Berges N; Pardo A; Fischer R; Ten Haaf A; Gattenlöhner S; Tur MK; Barth S
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1049-61. PubMed ID: 25433506
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
[TBL] [Abstract][Full Text] [Related]
10. Loss of MEF2D expression inhibits differentiation and contributes to oncogenesis in rhabdomyosarcoma cells.
Zhang M; Truscott J; Davie J
Mol Cancer; 2013 Nov; 12(1):150. PubMed ID: 24279793
[TBL] [Abstract][Full Text] [Related]
11. CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV.
Pressey JG; Haas MC; Pressey CS; Kelly VM; Parker JN; Gillespie GY; Friedman GK
Pediatr Blood Cancer; 2013 Jan; 60(1):45-52. PubMed ID: 22408058
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.
Chadalapaka G; Jutooru I; Sreevalsan S; Pathi S; Kim K; Chen C; Crose L; Linardic C; Safe S
Int J Cancer; 2013 Feb; 132(4):795-806. PubMed ID: 22815231
[TBL] [Abstract][Full Text] [Related]
13. Intracellular trafficking as a determinant of AS-DACA cytotoxicity in rhabdomyosarcoma cells.
Wolf SJ; Huynh T; Bryce NS; Hambley TW; Wakelin LP; Stewart BW; Catchpoole DR
BMC Cell Biol; 2011 Aug; 12():36. PubMed ID: 21861933
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
[TBL] [Abstract][Full Text] [Related]
15. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of GLI1 in vincristine-resistant rhabdomyosarcoma and Ewing sarcoma.
Yoon JW; Lamm M; Chandler C; Iannaccone P; Walterhouse D
BMC Cancer; 2020 Jun; 20(1):511. PubMed ID: 32493277
[TBL] [Abstract][Full Text] [Related]
17. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells.
Cassandri M; Pomella S; Rossetti A; Petragnano F; Milazzo L; Vulcano F; Camero S; Codenotti S; Cicchetti F; Maggio R; Festuccia C; Gravina GL; Fanzani A; Megiorni F; Catanoso M; Marchese C; Tombolini V; Locatelli F; Rota R; Marampon F
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639012
[TBL] [Abstract][Full Text] [Related]
18. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
[TBL] [Abstract][Full Text] [Related]
19. LEF1 reduces tumor progression and induces myodifferentiation in a subset of rhabdomyosarcoma.
Dräger J; Simon-Keller K; Pukrop T; Klemm F; Wilting J; Sticht C; Dittmann K; Schulz M; Leuschner I; Marx A; Hahn H
Oncotarget; 2017 Jan; 8(2):3259-3273. PubMed ID: 27965462
[TBL] [Abstract][Full Text] [Related]
20. Pannexin 1 inhibits rhabdomyosarcoma progression through a mechanism independent of its canonical channel function.
Xiang X; Langlois S; St-Pierre ME; Barré JF; Grynspan D; Purgina B; Cowan KN
Oncogenesis; 2018 Nov; 7(11):89. PubMed ID: 30459312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
